Prevalence and Associated Risk Factors of Cerebral Microbleeds in Egyptian Patients with Acute Ischemic Stroke and Atrial Fibrillation

BackgroundFew studies addressed the prevalence of cerebral microbleeds (CMB) and associated risk factor profile in Egyptian ischemic cerebral stroke patients with atrial fibrillation (AF).MethodsThe prevalence of CMB was estimated in 150 cases of AF ischemic stroke patients and compared to the prevalence in 150 age- and sex-matched controls of ischemic stroke patients without AF. CMB-associated risk factors were identified by comparing AF ischemic stroke patients with and without CMB. All participants were subjected to complete general, neurological examination, and magnetic resonance imaging.ResultsThe prevalence of CMBs in ischemic stroke with and without AF was 40.7% and 49.3%, respectively. Age, hypertension, diabetes mellitus, past history of stroke, antiplatelet, anticoagulant, National Institutes of Health Stroke Scale, CHA₂DS₂VASc, and white matter lesions (WML) were significant risk factors associated with CMB on univariate analysis. On multivariable logistic regression analysis, age (odds ratio [OR] 1.1, confidence interval [CI] 1.02-1.13), hypertension (OR 3.2, CI 1.19-8.81), anticoagulant (OR 3.3, CI 1.17-9.40), and WML (OR 9.6, CI 3.49-26.3) were the only independent risk factors associated with the presence of CMBs.ConclusionsAF in ischemic stroke patients was not associated with higher prevalence of CMBs. Old age, hypertension, anticoagulant treatment, and WML were the independent risk factors associated with CMB in AF ischemic stroke patients. Our results suggest that elderly hypertensive AF ischemic stroke patients maintained on anticoagulant therapy should be screened for the incidence of CMBs and monitored regularly for the development of intracerebral hemorrhage.     

急性缺血性卒中患者脑微出血相关因素分析

【摘要】
目的 探讨急性缺血性卒中患者合并脑微出血（cerebral microbleeds,CMB）的情况及其相关因素。
方法 本研究采用单中心、前瞻性研究方法,连续收集2011年1月～2012年6月于北京市第六医院神经内科住院的急性缺血性卒中患者302例,根据有无CMB将患者分为有CMB组（83例）和无CMB组（219例）,比较两组间一般临床资料、生化指标及影像学特点是否存在差异,并采用多因素逐步Logistic回归模型分析CMB发生的独立危险因素。
结果 302例患者中,合并有CMB者83例（27.5%）,其中年龄（t=3.67,P<0.001）、高血压（χ2=4.76,P=0.03）、卒中史（χ2=5.46,P=0.02）、纤维蛋白原（t=2.33,P=0.02）、腔隙性脑梗死数目（Z=-5.04,P<0.001）以及脑白质疏松程度评分（Z=-7.88,P<0.001）两组间比较差异具有显著性。Logistic回归分析显示,纤维蛋白原［比值比（odds ratio,OR）1.469,95%可信区间（confidence interval,CI）1.366～1.602;P=0.037］、腔隙性脑梗死数目（OR 1.636,95%CI 1.200～2.231;P=0.002）以及脑白质疏松程度评分（OR 1.700,95%CI 1.502～1.980;P<0.001）是急性缺血性卒中患者CMB发生的独立危险因素。
结论 CMB的发生与纤维蛋白原含量、腔隙性脑梗死数目以及脑白质疏松程度相关。     

Pharmacotherapy for Patients with Atrial Fibrillation and Cerebral Microbleeds

Background: Patients with cerebral microbleeds have increased risk of intracranial hemorrhage and ischemic stroke. No trial specifically informs antithrombotic therapy for patients with cerebral microbleeds and atrial fibrillation. We investigated the safety of anticoagulation versus no anticoagulation with regard to cerebrovascular outcomes and mortality. Methods: All consecutive atrial fibrillation patients from 2015 to 2018 with MRI evidence of ≥1 cerebral microbleed at time of imaging were reviewed. Patients were treated with warfarin, direct oral anticoagulants, or neither. Primary outcome was all-cause mortality informed by National Death Registry and the composite of ischemic and hemorrhagic stroke. All statistical tests were 2-sided and significant at P < .05. Results: The median interval from patient identification until the end of electronic health record surveillance was 9.93 months (interquartile range, 2.83-19.17 months). We identified 308 atrial fibrillation patients with cerebral microbleeds; 128(41.6%) were on warfarin, 88(28.6%) on direct oral anticoagulants, and 92(29.9%) on neither. Over the surveillance interval, 87 deaths, 51 ischemic strokes, and 14 hemorrhagic strokes occurred. The estimated likelihoods of the composite stroke outcome and ischemic stroke only did not differ significantly among the 3 groups. However, patients taking direct oral anticoagulants had a significantly smaller likelihood of all-cause mortality than patients who were not anticoagulated (adjusted hazard ratio: .44[.23, .83], P=.012). Conclusions: In patients with coprevalent atrial fibrillation and cerebral microbleeds, we did not detect differences in subsequent ischemic stroke, hemorrhagic stroke, or both, comparing warfarin, direct oral anticoagulants, or neither. Patients treated with direct oral anticoagulants had better survival than nonanticoagulated patients.     

缺血性卒中患者脑内微出血特点及危险因素的研究

目的 探讨脑内微出血在缺血性卒中患者中的发生率及在脑内各区域的分布情况,观察缺血性卒中亚型之间微出血发生率的差异,初步分析其相关因素及其与腔隙性脑梗死、脑白质病变等微小血管病变程度之间的关系。方法 连续入选261例心源性栓塞型、大动脉粥样硬化型及小动脉闭塞型3个亚型的缺血性卒中患者。记录患者一般临床资料及实验室检查结果,应用头颅磁共振梯度回波T2*加权成像（gradient-echoT2*-weighted,GRE-T2*）观察脑内微出血的数目及部位,同时观察腔隙性脑梗死数目和部位以及脑白质病变程度。结果 80例患者（30.70%）存在脑内微出血,数目为1～109个。微出血最常见于皮质-皮质下区（46.09%）,其次位于基底节区（27.80%）。各亚型中小动脉闭塞型患者脑内微出血的发生率最高（53.30%）。高血压、腔隙性脑梗死数目及脑白质改变程度为缺血性卒中患者脑内微出血发生的独立危险因素,比值比（odds ratio,OR）分别为4.364、1.190和1.310;脑内微出血的分级与腔隙性梗死分级（r =0.519,P <0.001）及白质改变程度（r =0.437,P <0.001）显著相关。结论 微出血在缺血性卒中患者特别是小动脉闭塞患者中发生率较高,微出血与腔隙性脑梗死数目及脑白质改变明显相关。     

卒中合并脑微出血的影像学研究

目的 探讨ICH和脑梗死患者合并脑微出血（cerebral microbleeds，CMBs）数量分级及部位分布差异。 方法 连续选取2017年8月-2018年12月在北京市大兴区人民医院神经内科病房住院且资料完整的 卒中患者，分为ICH和脑梗死两组。收集患者发病2周内头颅MRI磁敏感加权成像影像，统计ICH与脑梗 死患者中CMBs数量分级及部位分布特点。 结果 共入组患者234例，其中ICH组79例，脑梗死组155例。ICH组合并CMBs 65例（82.3%），其中 CMBs＞5个的患者41例（51.9%）；脑梗死组合并CMBs 73例（47.1%），其中CMBs＞5个的患者21例 （13.6%），两组差异有统计学意义（P＜0.001）。ICH组中，CMBs同时累及脑叶和深部脑组织的患者40例 （50.6%）；脑梗死组中，CMBs同时累及脑叶和深部脑组织的患者25例（16.1%），两组差异有统计学意 义（P＜0.001）。 结论 CMBs病灶＞5个多见于ICH患者；CMBs同时累及脑叶及深部脑组织多见于ICH患者。     

心房颤动合并急性缺血性脑卒中的溶栓及抗凝治疗研究进展

急性缺血性脑卒中是常见病、多发病。心房颤动(房颤)是临床上常见的心律失常,尤以非瓣膜性房颤为著。房颤合并急性缺血性脑卒中的患者临床常见,且病情重、出血转化率高、复发率高,给治疗带来一定的难度。重组组织型纤溶酶原激活剂是目前治疗急性缺血性脑卒中最有效的药物,可减少急性缺血性脑卒中患者的致残率;口服抗凝药可减少房颤相关急性缺血性脑卒中的复发;抗血小板治疗对房颤合并急性缺血性脑卒中患者也有一定的二级预防作用。鉴于房颤合并急性缺血性脑卒中所特有的临床特征,选择适宜的药物治疗至关重要。     

Cerebral Microbleeds are Associated with Higher Mortality Among Ischemic Stroke Patients

Background

Several studies have shown that cerebral microbleeds (CMBs) increase the risk of long-term stroke-related mortality. The purpose of this study was to determine if the existence and burden of CMBs are a predictor of in-hospital death among patients with acute ischemic stroke (AIS).

嘉兴地区急性缺血性卒中合并心房颤动患者抗凝治疗现状分析

目的 调查嘉兴地区急性缺血性卒中合并心房颤动患者的抗凝治疗现状。 方法 回顾性分析2016年1月-2020年12月基于CT临床数据采集系统对卒中医疗质量改进的研究登 记库-Ⅱ（computer analysing system to improve stroke management quality evaluation-Ⅱ,CASE-Ⅱ）中的 嘉兴地区卒中中心登记的急性缺血性卒中合并心房颤动住院患者的信息。根据患者出院是否带有抗 凝药物分为出院抗凝组与出院未抗凝组,比较两组患者的基本特征,采用logistic回归分析出院抗凝 药物使用的影响因素;并进一步在既往诊断心房颤动且卒中高危（CHA2DS2-VASc≥2分）患者亚群中分 析抗凝药物使用的影响因素。 结果 共纳入患者2005例,平均年龄77±8岁,男性979例（48.8%）,NIHSS中位评分5（2～13）分。 无抗血栓治疗禁忌证患者1817例,出院时带抗血栓药物比例为83.9%（1525/1817）,其中抗凝药 物比例为41.3%（750/1817）。年龄（OR 0.964,95%CI 0.952～0.976）,基线NIHSS评分（OR 0.935, 95%CI 0.920～0.951）,住院时间（OR 1.045,95%CI 1.025～1.066）,深静脉血栓（OR 2.797, 95%CI 1.472～5.311）,住院期间是否发生任意的颅内出血（OR 0.085,95%CI 0.038～0.188）、消化 道出血（OR 0.503,95%CI 0.257～0.985）、肺炎（OR 0.646,95%CI 0.488～0.856）是急性缺血性卒中 合并心房颤动患者出院接受抗凝治疗与否的独立影响因素。既往诊断心房颤动且卒中高危患者接受 抗凝治疗比例仅为16.0%（153/954）,低龄（OR 0.957,95%CI 0.938～0.975）、低收缩压（OR 0.985, 95%CI 0.977～0.993）、卒中/TIA病史（OR 2.773,95%CI 1.954～3.936）是其接受抗凝治疗的独立保护 因素。 结论 嘉兴地区急性缺血性卒中合并心房颤动患者的抗凝治疗率较低,低龄、低基线NIHSS评分、 长住院时间、合并深静脉血栓的患者更多接受抗凝治疗,住院期间发生颅内出血、消化道出血和肺炎 的患者更少接受抗凝治疗。     

心房颤动相关缺血性卒中的研究进展

【摘要】 心房颤动是临床上常见的心律失常,其患病率随着年龄增长而增加。由于无症状性心房颤 动的存在,心房颤动发病率及患病率均不完善。心房颤动因并发缺血性卒中而具有很高的致残率、致 死率。口服抗凝药是目前预防心房颤动血栓栓塞并发症最有效的方法。近年来,随着心房颤动发病 率的日益增长及缺血性卒中病因研究的逐渐细化,伴心房颤动的缺血性卒中相关研究引起了学界的广 泛关注。本文就相关研究热点做一综述。